At baseline, OSDI scores were comparable between groups (median 30 in both, p = 0.88)
Regulation of cell function by methionine oxidation and reduction
For more details on obesity pharmacotherapies that may benefit MASH, refer to Appendix 3
Wang, J., Li, M., Geng, Z., Khattak, S., Ji, X., Wu, D., & Dang, Y
A: According to published clinical trial data for FDA-approved medications: Wegovy (semaglutide 2.4 mg): Average 15% body weight loss at 68 weeks (approximately 33 pounds for 220-pound individual) Zepbound (tirzepatide 15 mg): Average 20% body weight loss at 72 weeks (approximately 44 pounds for 220-pound individual) Critical Context : These represent average results from controlled clinical trials where participants also followed reduced-calorie diets and increased physical activity
The 5 mg vials cost $399